Testosterone and Estrogen: Wondrous Hormones

Episode Summary

Executive Summary: The episode dismantles simplistic ideas that estrogen is only a “female hormone” and testosterone only a “male hormone,” showing both are steroid hormone families with overlapping roles in development, mood, bone health, muscle function, sexuality, and behavior. It also revisits the history, misconceptions, and medical uses of hormone therapy, including menopause treatment, trans care, puberty blockers, and the limits of using hormones to explain aggression or identity.

Main Topics: Hormones are not strictly male or female (Priority: 5/5): The hosts explain that estrogen and testosterone are both present in all sexes and affect far more than reproduction, challenging binary public assumptions. Historical origins of hormone science (Priority: 4/5): The discussion traces early hormone research from animal organ experiments to the coining of the term 'hormone' and the origin of the word estrogen. Estrogen as a family of hormones (Priority: 5/5): They outline estrone, estradiol, and estriol, emphasizing estrogen’s roles in bone, muscle, brain function, skin elasticity, endurance, mood, and movement. Testosterone development and function (Priority: 5/5): The episode covers testosterone’s role in fetal development, puberty, bone growth, libido, and brain effects, while noting that behavior is not directly determined by blood testosterone alone. Hormones, behavior, and the limits of causation (Priority: 5/5): The hosts examine research on aggression, confidence, winning/losing, prison populations, and social expectations, stressing that hormones often respond to context rather than simply cause behavior. Medical hormone therapy and risk communication (Priority: 4/5): The episode reviews menopause hormone therapy, the Premarin/PremPro history, and how media coverage overstated risks, influencing decades of public fear. Trans, intersex, and puberty-blocker care (Priority: 4/5): They note hormone therapy’s role for trans and intersex people and explain how puberty blockers can pause irreversible changes while identity and treatment decisions are made.

Key Arguments: Estrogen and testosterone are both shared across sexes; the old male/female split is an oversimplification. Estrogen is important not just for reproduction but for bone integrity, muscle maintenance, endurance, brain activity, skin elasticity, and movement. Testosterone influences development, libido, and certain body changes, but it does not cleanly map onto aggression or masculinity. Hormonal effects depend on timing, tissue, brain region, and interactions with other hormones and neurotransmitters, so simple cause-and-effect claims are unreliable. Some behavioral effects attributed to blood testosterone may actually reflect locally produced testosterone in the brain. Hormone replacement therapy, especially transdermal estrogen, can be beneficial and was widely mischaracterized after the Women’s Health Initiative study. Puberty blockers and hormone therapy can be important tools for trans and intersex care and for treating precocious puberty.

Data Points: Premarin market position: Highest-selling drug in the United States by 1992 - Illustrates how widely hormone therapy was used before risk fears reshaped prescribing. Premarin revenue: $1 billion in 1997 - Shows the scale of the drug’s popularity before the drop in usage. Humira revenue: $21 billion in 2022 - Used as a comparison to show how much larger today’s blockbuster drug market is. Breast cancer risk increase with PremPro: 26% relative increase - Described as alarming in headlines but modest in absolute terms. Breast cancer absolute risk with PremPro: 2.33% to 2.99% - The transcript contrasts relative vs absolute risk to explain public misunderstanding. Additional breast cancer cases: 8 per 10,000 users - Estimated excess cases among women taking hormone replacement therapy. Menopause hormone age guidance: Under age 60 / especially under age 70 - The discussion notes that starting hormone therapy closer to menopause is generally considered safer. Estrogen in men: 10 to 50 picograms per milliliter - Presented as a typical range for males. Estrogen in premenopausal women: 30 to 40 picograms per milliliter - Presented as a typical range that varies across the menstrual cycle. Estrogen in postmenopausal women: 0 to 30 picograms per milliliter - Shows the postmenopausal decline but not complete absence. Testosterone in adult men: 300 to 1,000 ng/dL - Typical range for adult males with 'normal T'. Testosterone in adult women: 15 to 70 ng/dL - Typical range for adult females. Childhood testosterone: Under 10 ng/dL - Noted as low in both boys and girls before puberty. Estimated annual testosterone decline: About 1% per year - Described as beginning in the 30s and affecting both men and women.

Pivotal Quotes: "If you have a lot of estrogen, you're female. A lot of testosterone, you're a male." — Josh/Chuck (discussion of common misconception): Introduces the episode’s central challenge to binary hormone thinking. "I learned: wow, this is, if we had just never considered estrogen female and testosterone male, I think our general understanding of those two hormones would be so much deeper." — Josh: Summarizes the episode’s thesis about misplaced cultural assumptions. "Hormones are simply chemical messengers that basically relay messages and trigger responses or keep responses from happening in the body." — Chuck: Provides the foundational definition used throughout the episode.

Implications: Listeners should rethink gendered assumptions about hormones and see hormone therapy as nuanced, evidence-based care. The episode also warns against overstating risks from headline science and supports more careful, individualized medical decision-making.